With Kymera’s clinical debut, targeted protein degradation gets its first RCT 

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm, late-stage cancer trials have allowed.

On Tuesday,  Kymera Therapeutics Inc. (NASDAQ:KYMR) announced it had initiated dosing in a randomized, double-blind, placebo-controlled Phase I trial of the company’s IRAK4 degrader KT-474. The trial is recruiting healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa, both inflammatory diseases driven by IL-1 receptor signaling...